Summary of key recommendations

Summary of Key Recommendations for the Treatment of Blood Cholesterol to Reduce ASCVD Risk in Adults

Class I
"1.Clinical ASCVD (includes acute coronary syndromes, history of MI, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, or peripheral arterial disease presumed to be of atherosclerotic origin)(Level of Evidence: A)" Age 75 y and no safety concerns: High-intensity statin Age >75 y or safety concerns: Moderate-intensity statin
"2.Primary prevention – Primary LDL-C ‡190 mg/dL(Level of Evidence: B)" Rule out secondary causes of hyperlipidemia Age !21 y: High-intensity statin
"3.Primary preventiondDiabetes 40–75 years of age and LDL-C 70–189 mg/dL Moderate-intensity statin(Level of Evidence: A)"
"4. Primary prevention – No diabetes 40–75 years of age and LDL-C 70–189 mg/dL Estimate 10-y ASCVD risk using the Risk Calculator based on the Pooled Cohort Equationsy in those NOT receiving a statin; estimate risk every 4–6 y(Level of Evidence: B)"

Class III (Harm)
"1. RECOMMENDATION 1 HERE (Level of Evidence: C)"
"2. RECOMMENDATION 2 HERE (Level of Evidence: C)"

Class III (No Benefit)
"1. RECOMMENDATION 1 HERE (Level of Evidence: C)"
"2. RECOMMENDATION 2 HERE (Level of Evidence: C)"

Class IIa
"1. RECOMMENDATION 1 HERE (Level of Evidence: C)"
"2. RECOMMENDATION 2 HERE (Level of Evidence: C)"

Class IIb
"1. RECOMMENDATION 1 HERE (Level of Evidence: C)"
"2. RECOMMENDATION 2 HERE (Level of Evidence: C)"